NEJM Evidence Issues Research Articles in December 2023 Edition
November 30, 2023
November 30, 2023
WALTHAM, Massachusetts, Nov. 30 -- NEJM Evidence, a peer-reviewed journal from New England Journal of Medicine Group that says it presents clinical trial design and decision-making, published research articles on the following topics in its December 2023 edition (Vol. 2, No. 12):
Original Articles:
* Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes
* RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
* Enz . . .
Original Articles:
* Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes
* RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
* Enz . . .